206 related articles for article (PubMed ID: 30514676)
1. [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].
Chen K; Liang H; Peng J; Zheng Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Nov; 38(11):1300-1305. PubMed ID: 30514676
[TBL] [Abstract][Full Text] [Related]
2. Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
Ma J; Zhang Y; Shen H; Kapesa L; Liu W; Zeng M; Zeng S
Tumour Biol; 2015 Dec; 36(12):9599-609. PubMed ID: 26142736
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):591-6. PubMed ID: 26714599
[TBL] [Abstract][Full Text] [Related]
4. Intertumoral Heterogeneity of CD3
Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
[TBL] [Abstract][Full Text] [Related]
5. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between mismatch repair proteins status and clinicopathological characteristics in sporadic colorectal cancer patients].
Xiao ZT; Zhang RX; Zhao Y; Peng JH; Lu SX; Zhang HZ; Ding PR; Wu XJ; Lu ZH; Li LR; Wan DS; Pan ZZ; Chen G
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(16):1248-1251. PubMed ID: 28441855
[No Abstract] [Full Text] [Related]
7. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
[TBL] [Abstract][Full Text] [Related]
8. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
9. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria.
Sun CY; Chiang JM; Chen TC; Hung HY; You JF
World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993
[TBL] [Abstract][Full Text] [Related]
10. LDH-A negatively regulates dMMR in colorectal cancer.
Zhang Y; Li J; Wang B; Chen T; Chen Y; Ma W
Cancer Sci; 2021 Aug; 112(8):3050-3063. PubMed ID: 34110068
[TBL] [Abstract][Full Text] [Related]
11. Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer.
Rico SD; Höflmayer D; Büscheck F; Dum D; Luebke AM; Kluth M; Hube-Magg C; Hinsch A; Möller-Koop C; Perez D; Izbicki JR; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Fraune C; Möller K; Menz A; Bernreuther C; Clauditz TS; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Lebok P; Burandt E; Krech T; Marx AH
Med Mol Morphol; 2021 Jun; 54(2):156-165. PubMed ID: 33373033
[TBL] [Abstract][Full Text] [Related]
12. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers.
Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N
Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889
[TBL] [Abstract][Full Text] [Related]
13. Deficient mismatch repair as a prognostic marker in stage II colon cancer patients.
Gkekas I; Novotny J; Fabian P; Nemecek R; Palmqvist R; Strigård K; Pecen L; Svoboda T; Gurlich R; Gunnarsson U
Eur J Surg Oncol; 2019 Oct; 45(10):1854-1861. PubMed ID: 31186203
[TBL] [Abstract][Full Text] [Related]
14. Saffron and Its Major Ingredients' Effect on Colon Cancer Cells with Mismatch Repair Deficiency and Microsatellite Instability.
Amin A; Farrukh A; Murali C; Soleimani A; Praz F; Graziani G; Brim H; Ashktorab H
Molecules; 2021 Jun; 26(13):. PubMed ID: 34202689
[TBL] [Abstract][Full Text] [Related]
15. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X
Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA ENST00000455974 plays an oncogenic role through up-regulating JAG2 in human DNA mismatch repair-proficient colon cancer.
Lao Y; Li Q; Li N; Liu H; Liu K; Jiang G; Wei N; Wang C; Wang Y; Wu J
Biochem Biophys Res Commun; 2019 Jan; 508(2):339-347. PubMed ID: 30473216
[TBL] [Abstract][Full Text] [Related]
17. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
[TBL] [Abstract][Full Text] [Related]
18. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
[TBL] [Abstract][Full Text] [Related]
19. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
[TBL] [Abstract][Full Text] [Related]
20. Tumor Budding
Karlberg M; Stenstedt K; Hallström M; Ragnhammar P; Lenander C; Edler D
Anticancer Res; 2018 Aug; 38(8):4713-4721. PubMed ID: 30061240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
